GlycoMimetics Inc - Company Profile

Powered by

All the data and insights you need on GlycoMimetics Inc in one report.

$ $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date GlycoMimetics Inc Strategy Report

  • Understand GlycoMimetics Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

GlycoMimetics Inc: Overview

Select Item

GlycoMimetics Inc (GlycoMimetics) is a clinical-stage biotechnology company that discovers and develops small molecule drugs for the treatment of cancer and inflammatory diseases. The company’s lead pipeline product, uproleselan, is being developed for the treatment of relapsed/refractory acute myeloid leukemia (AML) in adults. GlycoMimetics designs galectin inhibitors for advancing treatment options for various diseases. The company designs and tests viral and bacterial entry inhibitors for dendritic cell receptors. GlycoMimetics uses proprietary glycobiology technology to develop treatments for diseases. It also offers clinical research programs. GlycoMimetics is headquartered in Rockville, Maryland, the US.

 Gain a 360-degree view of GlycoMimetics Inc and make more informed decisions for your business Gain a 360-degree view of GlycoMimetics Inc and make more informed decisions for your business Find out more
Headquarters United States of America
Address 9708 Medical Center Drive, Rockville, Maryland, 20850
Website glycomimetics.com
Telephone 1 240 2431201
No of Employees 35
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange GLYC (NASD)
Revenue (2022) $10,000 -86.7% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ 21% (2022 vs 2021)
Market Cap* $147.0M
Net Profit Margin (2022) XYZ -492.8% (2022 vs 2021)
* As of and is in US$
View GlycoMimetics Inc financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

GlycoMimetics Inc premium industry data and analytics

20+

Clinical Trials

Determine GlycoMimetics Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

20+

Catalyst Calendar

Proactively evaluate GlycoMimetics Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

12+

Pipeline Drugs

Identify which of GlycoMimetics Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

9

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

3

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

Products and Services

Products
Pipeline
GMI-1687 - SCD Vaso-Occlusive Crisis & AML
GMI-2093 - Fibrosis and Oncology
XYZ
XYZ
XYZ
Understand GlycoMimetics Inc portfolio and identify potential areas for collaboration Understand GlycoMimetics Inc portfolio and identify potential areas for collaboration Find out more
Image for loader

Competitor Comparison

Key Parameters GlycoMimetics Inc Concert Pharmaceuticals Inc Humanigen Inc ImmunityBio Inc Anthera Pharmaceuticals Inc
Headquarters United States of America United States of America United States of America United States of America United States of America
City Rockville Lexington Short Hills San Diego Hayward
State/Province Maryland Massachusetts New Jersey California California
No. of Employees 35 - 6 628 21
Entity Type Public Private Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Timothy R. Pearson Chairman Executive Board 2019 55
Harout Semerjian Chief Executive Officer; President Senior Management 2021 52
Brian Hahn Chief Financial Officer; Senior Vice President Senior Management 2019 48
Edwin Rock, M.D Chief Medical Officer; Senior Vice President Senior Management 2022 62
Bruce Johnson Chief Commercial Officer; Senior Vice President Senior Management 2022 55
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into GlycoMimetics Inc key executives to enhance your sales strategy Gain insight into GlycoMimetics Inc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward